We are live on ! Find out more
GD

Grandfield & Dodd Portfolio holdings

AUM $1.77B
1-Year Est. Return 23.43%
This Fund
S&P 500
This Quarter Est. Return
+5.21%
1 Year Est. Return
+23.43%
3 Year Est. Return
+55.25%
5 Year Est. Return
+78.92%
10 Year Est. Return
+317.48%
AUM
$1.01B
AUM Growth
+$51.4M
Cap. Flow
+$4.67M
Cap. Flow %
0.46%
Top 10 Hldgs %
30.68%
Holding
182
New
9
Increased
47
Reduced
78
Closed
1

Top Buys

Rank Stock Value
1
BLKB icon
Blackbaud
BLKB
+$2.01M
2
ALC icon
Alcon
ALC
+$1.1M
3
CTSH icon
Cognizant
CTSH
+$1.02M
4
ABB
ABB Ltd
ABB
+$986K
5
USB icon
US Bancorp
USB
+$917K

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$1.21M
2
NVS icon
Novartis
NVS
+$1.19M
3
MSFT icon
Microsoft
MSFT
+$815K
4
DOX icon
Amdocs
DOX
+$732K
5
RTX icon
RTX Corp
RTX
+$648K

Sector Composition

Rank Sector Weight
1 Technology 25.56%
2 Healthcare 16.99%
3 Financials 12.14%
4 Consumer Staples 10.6%
5 Industrials 9.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PM icon
101
Philip Morris
PM
$314B
$829K 0.08%
10,561
-143
-1% -$11.8K
DD icon
102
DuPont de Nemours
DD
$18.5B
$816K 0.08%
8,663
-3,973
-31% -$474K
ISRG icon
103
Intuitive Surgical
ISRG
$128B
$811K 0.08%
4,638
– –
V icon
104
Visa
V
$707B
$798K 0.08%
4,600
-140
-3% -$22.9K
VV icon
105
Vanguard Large-Cap ETF
VV
$51.6B
$765K 0.08%
5,680
+195
+4% +$25.8K
GLD icon
106
SPDR Gold Trust
GLD
$130B
$763K 0.08%
5,727
– –
INCY icon
107
Incyte
INCY
$25.4B
$756K 0.07%
8,895
+652
+8% +$52.3K
NBIX icon
108
Neurocrine Biosciences
NBIX
$18.3B
$727K 0.07%
8,611
+730
+9% +$59.9K
RDS.A
109
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$722K 0.07%
11,098
– –
CSX icon
110
CSX Corp
CSX
$93.7B
$704K 0.07%
27,300
– –
BA icon
111
Boeing
BA
$167B
$702K 0.07%
1,928
-95
-5% -$34.6K
BMY icon
112
Bristol-Myers Squibb
BMY
$130B
$697K 0.07%
15,374
-277
-2% -$12.9K
VEU icon
113
Vanguard FTSE All-World ex-US ETF
VEU
$64.9B
$697K 0.07%
13,670
+900
+7% +$45.4K
LLY icon
114
Eli Lilly
LLY
$1.09T
$656K 0.06%
5,925
-200
-3% -$23.6K
SCHW
115
Charles Schwab
SCHW
$185B
$647K 0.06%
16,092
– –
BMRN icon
116
BioMarin Pharmaceuticals
BMRN
$12B
$645K 0.06%
7,533
+665
+10% +$56.9K
AMZN icon
117
Amazon
AMZN
$2.45T
$625K 0.06%
6,600
+20
+0.3% +$1.86K
J icon
118
Jacobs Solutions
J
$16.2B
$614K 0.06%
8,798
-336
-4% -$21.7K
MCD icon
119
McDonald's
MCD
$193B
$600K 0.06%
2,887
-117
-4% -$23.2K
FISV
120
Fiserv Inc
FISV
$29.6B
$592K 0.06%
6,496
-800
-11% -$70.1K
ALXN
121
DELISTED
Alexion Pharmaceuticals
ALXN
$584K 0.06%
4,460
+432
+11% +$55.7K
NEE icon
122
NextEra Energy
NEE
$186B
$583K 0.06%
11,380
– –
OMC icon
123
Omnicom Group
OMC
$23.6B
$583K 0.06%
7,111
– –
FUL icon
124
H.B. Fuller
FUL
$2.99B
$561K 0.06%
12,094
– –
ED icon
125
Consolidated Edison
ED
$41.3B
$539K 0.05%
6,146
– –
3 4
5
6 7

Similar funds

HHAM
HITE Hedge Asset Management Braintree, Massachusetts $1.77B AUM 38.67% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.77B AUM 17.63% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
BCMIO
Beacon Capital Management Inc (Ohio) Dayton, Ohio $1.78B AUM 14.7% 1-Year Est. Return
UF
Univest Financial Souderton, Pennsylvania $1.78B AUM 22.52% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return

Grandfield & Dodd's Q2 2019 Portfolio in Review

As of Q2 2019, Grandfield & Dodd held 182 positions worth $1.01B, up 5.4% from $960M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Grandfield & Dodd's Q2 2019 filing shows 9 new, 47 increased, 78 reduced and 1 closed positions. Its largest new stake was Alcon: 18,816 shares worth $1.17M. The largest sale was Merck, an estimated $1.21M.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.

  • Grandfield & Dodd's largest Q2 2019 buy was Alcon: 18,816 shares worth $1.17M.
  • Grandfield & Dodd added most to Blackbaud in Q2 2019, an estimated $2.01M increase.
  • Grandfield & Dodd's biggest Q2 2019 reduction was Merck, cutting an estimated $1.21M.
  • Grandfield & Dodd fully exited Vanguard FTSE Europe ETF in Q2 2019, selling an estimated $218K.
  • Grandfield & Dodd's ten largest holdings make up 31% of its $1.01B portfolio in Q2 2019.
  • Grandfield & Dodd opened 9 new positions and closed 1 in Q2 2019.
  • Grandfield & Dodd's portfolio value rose 5.4% quarter-over-quarter to $1.01B.

Based on Grandfield & Dodd's 13F filing for Q2 2019, filed 29 Jul 2019.